OPRXMEDIUM SIGNALFINANCIAL10-K

OptimizeRx demonstrated solid operational growth with revenue increasing 18.8% while meaningfully strengthening its balance sheet through debt reduction and cash accumulation.

The company appears to be executing well operationally with healthy revenue and gross profit expansion, while simultaneously improving its financial position by reducing total debt by 23.3% and building cash reserves. However, the reduction in share buybacks from $20M to $7.5M may signal management is becoming more conservative with capital allocation, possibly reflecting concerns about market conditions or preserving liquidity for strategic investments.

Comparing 2026-03-12 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

OptimizeRx delivered strong financial performance with revenue growing 18.8% to $109.4M and gross profit expanding 23.9% to $73.6M, indicating improving operational efficiency. The balance sheet strengthened considerably, with cash and equivalents growing 74.6% to $23.4M while total debt decreased 23.3% to $26.3M, demonstrating effective debt management and liquidity building. The company scaled back share repurchases significantly from $20M to $7.5M, suggesting a shift toward more conservative capital allocation while maintaining modest growth in operating expenses.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+74.6%
$13.4M→$23.4M

Cash position surged 74.6% — strong cash generation or capital raise providing significant financial cushion.

Share Buybacks
Cash Flow
-62.4%
$20.0M→$7.5M

Buyback activity reduced 62.4% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-48.2%
$112K→$58K

Capex reduced 48.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Gross Profit
P&L
+23.9%
$59.4M→$73.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Debt
Balance Sheet
-23.3%
$34.3M→$26.3M

Debt reduced 23.3% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
+20.9%
$27.7M→$33.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Current Assets
Balance Sheet
+19.9%
$54.0M→$64.7M

Current assets grew 19.9% — improving short-term liquidity or inventory/receivables build.

Revenue
P&L
+18.8%
$92.1M→$109.4M

Revenue growing 18.8% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+14%
$18.7M→$21.3M

Current liabilities rose 14% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
-10.2%
$54.2M→$48.6M

Liabilities reduced 10.2% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-20
ADDED
Unless otherwise specified or the context otherwise requires, when used in this Annual Report on Form 10-K, the terms we, our, us, OptimizeRx, or the Company refer to OptimizeRx Corporation and its subsidiaries on a consolidated basis.
We are dependent on a concentrated group of customers, and the loss of one or more of any of the pharmaceutical brands that purchase our solutions could cause our revenue to decline.
We expect to face increasing competition in the markets of our solutions.
If our customers drug prices are reduced as a result of MFN pricing initiatives or other similar regulations, our business could be adversely affected by our customers reducing their marketing and advertising spend.
Business General OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.
Form 10-K Summary 35 i FORWARD LOOKING STATEMENT This Annual Report on Form 10-K contains statements that relate to future events and expectations and, as such, constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Unless otherwise specified or the context otherwise requires, when used in this Annual Report on Form 10-K, the terms we, our, us, OptimizeRx, or the Company refer to OptimizeRx Corporation and its subsidiaries.
If we are unable to maintain our contracts with electronic prescription platforms and electronic health record systems, our business will suffer.
The markets in which we operate are competitive, continually evolving and, in some cases, subject to rapid change.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →